Drug Trial Radar · NCT06141460
Safety and Efficacy of RRG001 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD)
Last checked: Nov 19, 2026Latest source record: Nov 14, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
48
Planned (sponsor's estimate)
Start
Dec 12, 2023
Primary completion
Apr 15, 2026
Study completion Dec 31, 2030
Sponsor
- Lead sponsor
- Shanghai Refreshgene Technology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 21, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase I/IIa, Dose-escalation and Dose-expansion Study to Evaluate the Safety and Efficacy of Single Subretinal Injection of RRG001 in Subjects With Neovascular Age-related Macular Degeneration
Conditions
- Neovascular Age-related Macular Degeneration
Interventions
RRG001Drug
Administered via Subretinal injection. Dosage form: injection solution.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and tolerabilityTime frame: Week 52
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Tianjin Medical University Eye Hospital
Tianjin, Tianjin Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.